Traditional Chinese medicine prescription, composition and medicine for treating neurodegenerative diseases

Abstract

The invention provides a traditional Chinese medicine prescription, a composition and a medicine for treating neurodegenerative diseases, and belongs to the technical field of biological medicines. The traditional Chinese medicine raw materials of the traditional Chinese medicine prescription comprise hericium erinaceus, turmeric and purslane, and the invention provides a traditional Chinese medicine composition with a hericium erinaceus extract, a turmeric extract and a purslane extract as components, and a medicine prepared based on the traditional Chinese medicine prescription and the traditional Chinese medicine composition. It is proved that the traditional Chinese medicine composition has a good treatment effect on experimental rat neurodegenerative diseases, can resist inflammation, reduce blood fat, protect neurons and the like, and has a good improvement effect on cognitive impairment and mobility disorder caused by the neurodegenerative diseases.

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to a traditional Chinese medicine prescription, a composition and a medicine for treating neurodegenerative diseases. Background Art

[0002] Neurodegenerative diseases refer to a series of diseases caused by the loss of neurons and their myelin sheaths. Chronic neurodegenerative diseases mainly include Alzheimer's disease (AD) and Parkinson's disease (PD), and their pathogenesis is complex and diverse. Existing evidence shows that pathological protein deposition, neuroinflammation and oxidative stress are the three key factors that cause neurodegenerative diseases.

[0003] The typical symptoms of AD are cognitive decline, manifested as memory impairment, language impairment, spatial orientation disorder, etc. In current research, a large amount of evidence shows that AD is caused by neuronal protein plaques and their related inflammatory responses. PD is a disease characterized by motor neuron degeneration, with typical symptoms such as stiffness, tremor, and imbalance. The results of many studies have shown that Parkinson's disease is caused by brain oxidative stress and related neuronal damage. These oxidative stress processes include mitochondrial dysfunction, neuronal damage, etc.

[0004] The research results so far show that the single-target treatment strategy seems unable to control the course of AD and PD. Therefore, multi-target, systemic drug combinations, as a potential new type of therapy, have gradually become a research hotspot for the treatment of neurodegenerative diseases. Summary of the invention

[0005] The present invention provides a Chinese medicinal formula, a composition and a medicine for treating neurodegenerative diseases. The Chinese medicinal formula, the Chinese medicinal composition and the medicine have the effects of anti-inflammatory, anti-oxidation and neuron protection, and have a good improvement effect on the decline of memory and mobility caused by neurodegenerative diseases.

[0006] The invention provides a traditional Chinese medicine prescription for treating neurodegenerative diseases, comprising the following traditional Chinese medicine raw materials: Hericium erinaceus, turmeric and purslane.

[0007] In a specific embodiment of the present invention, the present invention comprises the following Chinese medicinal raw materials in parts by weight: 100-600 parts by weight of Hericium erinaceus, 30-100 parts by weight of turmeric and 90-150 parts by weight of purslane.

[0008] The invention provides a traditional Chinese medicine composition having a therapeutic effect on neurodegenerative diseases, comprising the following components: a Hericium erinaceus extract, a turmeric extract and a purslane extract.

[0009] In a specific embodiment of the present invention, the following components are included in parts by weight: 10 to 120 parts by weight of Hericium erinaceus extract, 1 to 20 parts by weight of Curcuma longa extract and 15 to 40 parts by weight of Portulaca oleracea extract.

[0010] In a specific embodiment of the present invention, the extraction solvents of the Hericium erinaceus extract, the Curcuma longa extract and the Portulaca oleracea extract are all polar solvents.

[0011] In a specific embodiment of the present invention, the polar solvent includes water and / or ethanol.

[0012] The present invention also provides the use of the above-mentioned Chinese medicine prescription or the above-mentioned Chinese medicine composition in the preparation of medicines for treating neurodegenerative diseases.

[0013] The present invention also provides a medicine for treating neurodegenerative diseases, comprising the above-mentioned Chinese medicine prescription or the above-mentioned Chinese medicine composition, and also comprising pharmaceutically acceptable excipients.

[0014] In a specific embodiment of the present invention, the active ingredients also include chemical drugs clinically used to treat neurodegenerative diseases.

[0015] In one embodiment of the present invention, the type of the drug includes oral drugs.

[0016] Beneficial effects: The Chinese medicine prescription of the present invention is prepared from Hericium erinaceus, turmeric, and purslane. The Hericium erinaceus of the present invention has antioxidant, immune regulation, anti-inflammatory and other activities, and can improve the spatial memory, learning ability and endurance of mice; curcumin in turmeric can neutralize free radicals, remove harmful oxidants, protect cells from oxidative damage, help delay aging, and prevent the occurrence of chronic diseases; promote the generation and activation of leukocytes, inhibit the release of inflammatory mediators, and reduce inflammatory reactions; reduce the damage to nerve cells, protect nerve cells, and help prevent and treat neurodegenerative diseases such as Alzheimer's disease; the main active ingredients of flavonoids and alkaloid small molecule compounds in purslane inhibit the production of Αβ and the formation of neurotoxicity induced by it through five aspects: Αβ regulates metabolism, Αβ induces oxidative stress, Αβ induces mitochondrial dysfunction, Αβ induces cell apoptosis, and tau protein regulates metabolism, improves the hyperphosphorylation of tau protein, and inhibits the apoptosis of nerve cells, and has a certain neuroprotective effect.

[0017] The Chinese medicine prescription, Chinese medicine composition and medicine of the present invention have good therapeutic effects on experimental rat neurodegenerative diseases, can resist inflammation, lower blood lipids, protect neurons, etc., and have good improvement effects on improving cognitive disorders and movement disorders caused by neurodegenerative diseases. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 The bar graph is the effect on NGF expression;

[0019] Figure 2 The bar graph shows the effect on climbing poles in Parkinson's mice;

[0020] Figure 3 The bar graph shows the effect of pulling force on Parkinson's mice;

[0021] Figure 4 The bar graph shows the effect on the number of platform jumping errors in dementia mice;

[0022] Figure 5 Bar graph showing the effect of the number of dark avoidance errors on dementia mice. DETAILED DESCRIPTION

[0023] The invention provides a traditional Chinese medicine prescription for treating neurodegenerative diseases, comprising the following traditional Chinese medicine raw materials: Hericium erinaceus, turmeric and purslane.

[0024] In a specific embodiment of the present invention, the traditional Chinese medicine prescription contains Hericium erinaceus, and the weight portion of the Hericium erinaceus is 100 to 600 weight portions, such as 200 weight portions.

[0025] In a specific embodiment of the present invention, the Chinese medicine prescription contains turmeric, and the weight portion of the turmeric is 30 to 100 weight portions, such as 50 weight portions.

[0026] In a specific embodiment of the present invention, the traditional Chinese medicine prescription comprises purslane, and the weight portion of the purslane is 90 to 150 weight portions, such as 100 weight portions.

[0027] In the present invention, the Hericium erinaceus has antioxidant, immune-regulating, anti-inflammatory and other activities, and can improve the spatial memory, learning ability and endurance of mice; the Hericium erinaceus and Hericium erinaceus ketone small molecule compounds contained therein can pass through the blood-brain barrier, promote the secretion of brain NGF, and repair damaged neurons. Curcumin in turmeric can neutralize free radicals, remove harmful oxidants, protect cells from oxidative damage, help delay aging, and prevent the occurrence of chronic diseases; promote the generation and activation of leukocytes, inhibit the release of inflammatory mediators, and reduce inflammatory reactions; reduce the damage to nerve cells, protect nerve cells, and help prevent and treat neurodegenerative diseases such as Alzheimer's disease. The main active ingredients of flavonoids and alkaloid small molecule compounds in Portulaca oleracea inhibit the production of Αβ and the formation of neurotoxicity induced by it through five aspects: Αβ regulates metabolism, Αβ induces oxidative stress, Αβ induces mitochondrial dysfunction, Αβ induces cell apoptosis, and tau protein regulates metabolism, improves the hyperphosphorylation of tau protein, and inhibits the apoptosis of nerve cells, and has a certain neuroprotective effect.

[0028] The invention provides a traditional Chinese medicine composition having a therapeutic effect on neurodegenerative diseases, comprising the following components: a Hericium erinaceus extract, a turmeric extract and a purslane extract.

[0029] The components of the traditional Chinese medicine composition of the present invention include Hericium erinaceus extract, and the weight portion of the Hericium erinaceus extract is 10 to 120 weight portions, such as 60 weight portions.

[0030] The components of the traditional Chinese medicine composition of the present invention include turmeric extract, and the weight portion of the turmeric extract is 1 to 20 weight portions, such as 10 weight portions.

[0031] The components of the traditional Chinese medicine composition of the present invention include purslane extract, and the weight portion of the purslane extract is 15 to 40 weight portions, such as 20 weight portions.

[0032] In a specific embodiment of the present invention, the extraction solvents of the Hericium erinaceus extract, the turmeric extract and the purslane extract are all polar solvents, such as water, ethanol or a mixture of water and ethanol. The Chinese medicine composition of the present invention has a protective effect on SH-SY5Y cells induced by Aβ1-42, can promote the synthesis of brain nerve growth factor (Nerve growth factor, NGF), inhibit neuroinflammation, increase mitochondria and improve cell function, has anti-inflammatory, antioxidant, hypolipidemic, neuroprotective effects, effectively improves cognitive ability, mobility and other symptoms, and has a good effect of improving the symptoms of neurodegenerative diseases.

[0033] The present invention also provides the use of the above-mentioned Chinese medicine prescription or the above-mentioned Chinese medicine composition in the preparation of medicines for treating neurodegenerative diseases.

[0034] The Chinese medicine prescription or Chinese medicine composition of the present invention can improve cognitive impairment and action disorder caused by neurodegenerative diseases, such as having a therapeutic effect on Alzheimer's disease and Parkinson's disease.

[0035] The present invention also provides a medicine for treating neurodegenerative diseases, comprising the above-mentioned Chinese medicine prescription or the above-mentioned Chinese medicine composition, and also comprising pharmaceutically acceptable excipients.

[0036] The medicine of the present invention can be made of the Chinese medicine prescription or the Chinese medicine composition as an active ingredient alone, or can be combined with chemical drugs for treating neurodegenerative diseases clinically as a common active ingredient, or can be prepared into a clinically acceptable preparation after adding pharmaceutically acceptable excipients, such as pyrroloquinolinequinone (PQQ). The PQQ mainly stimulates mitochondrial growth, increases the number and activity of mitochondria; has a therapeutic effect on neurasthenia, helps to improve insomnia and dreaminess; improves memory by improving neuronal damage; and assists in anti-fatigue and anti-aging effects.

[0037] The present invention does not specifically limit the preparation method of the drug. The Chinese medicine composition can be directly prepared into a clinically acceptable preparation or added with pharmaceutically acceptable excipients. The preparation is an oral preparation, such as an oral solid preparation, including granules, capsules or tablets, etc.; of course, it can also be prepared into a liquid preparation, such as an oral liquid, a mixture, a syrup or a decoction, etc.

[0038] To further illustrate the present invention, the Chinese medicinal prescriptions, compositions and medicines for treating neurodegenerative diseases provided by the present invention are described in detail below in conjunction with examples, but they should not be construed as limiting the scope of protection of the present invention.

[0039] Example 1

[0040] Take 400g of Hericium erinaceus, 100g of turmeric and 100g of purslane, add 10 times of water to soak for 30 minutes, and then decoct twice, each time for 1 hour. Combine the two decoctions, filter, and concentrate to a thick paste with a relative density of 1.05-1.20 (80°C), add 100g of dextrin, stir, dry, crush into fine powder, add 50g of dextrin, mix well, granulate, and dry to obtain granules.

[0041] Example 2

[0042] Take 400 kg of Hericium erinaceus, crush it through a 10-mesh sieve, add 4000 L of a mixture of water and ethanol in a ratio of 1:9, soak it overnight at a temperature of 20-60°C, percolate for 12-24 hours, and filter; the remaining medicinal residue is heated and extracted twice with water in a volume 10 times the amount of the feed, and filtered. Combine all the extracts, recover the ethanol, concentrate at low temperature (not higher than 60°C), add 80 kg of dextrin and dry it to obtain 160 kg of Hericium erinaceus extract. The Hericium erinaceus extract contains hericin, hericium erinone, alkaloids and unsaturated fatty acids, etc., which have a fat-soluble effective substance content of more than 10% (m / m), and also contains water-soluble effective substances such as polysaccharides and polypeptides.

[0043] Take 100 kg of turmeric, crush it through a 10-mesh sieve, add 1000 L of a mixture of water and ethanol in a ratio of 1:8, soak overnight at 20-60°C, percolate for 12-24 hours, filter, recover ethanol from the obtained extract, concentrate at low temperature (not higher than 60°C), concentrate to a clear paste of 1.0-1.1 (60°C), defat with petroleum ether, add 5 kg of povidone, stir, concentrate, dry, and prepare 10 kg of extract. The content of curcuminoid compounds in the turmeric extract is higher than 10% (m / m).

[0044] Take 100 kg of purslane, crush it and pass it through a 10-mesh sieve, add 1000 L of a 5:5 mixture of water and ethanol, heat and reflux to extract once, filter, recover the ethanol from the obtained extract, concentrate it, add 15 kg of dextrin, stir and dissolve it, and then dry it to obtain 30 kg of purslane extract.

[0045] Example 3

[0046] The Hericium erinaceus extract, turmeric extract and purslane extract prepared in Example 2 were mixed, 2 kg of pyrroloquinoline quinone (PQQ) was added, mixed, granulated, dried, and granulated to obtain granules. 20 kg of microcrystalline cellulose and 0.5 kg of magnesium stearate were added, tableted, and coated to obtain film-coated tablets.

[0047] Example 4

[0048] Study Example 3 Granules for Aβ 1-42 (Shanghai Yuanye, S40691) induced SH-SY5Y cell dementia model, specifically:

[0049] 1) Cell culture: Cells were cultured with a mixture of 10% fetal bovine serum and 1% penicillin-streptomycin in RPMI1640 basal medium, placed in a CO2 incubator (37°C, 5% CO2) for static culture, and the medium was changed every other day. When the cells grew to 90% of the bottom of the bottle, they were digested and passaged with 0.25% trypsin, and cells in the logarithmic growth phase were selected for experiments;

[0050] 2) Effect on the growth of normal SH-SY5Y cells: SH-SY5Y cells digested into a single cell suspension were inoculated into a 96-well plate with 5000 cells per well. After overnight attachment, different concentrations of the granule solution of Example 3 were added to continue culturing the cells for 24 h. The cell growth was detected by CCK-8 method to determine the subsequent administration concentration of the granules of Example 3. Compared with the control group, as the concentration increased, the granules of Example 3 showed a certain inhibitory effect on the growth of SH-SY5Y cells, and there was a dose-dependency. When the concentration was lower than 25 mg / mL, 85% of the cells were able to grow normally, which can be explained that the granules of Example 3 were less toxic to the cells. When the concentration was lower than 12.5 mg / mL, more than 95% of the cells were able to grow normally. Therefore, 12.5 mg / mL was determined to be a non-toxic concentration for the cells. The concentration of the granules of Example 3 was selected to be lower than 12.5 mg / mL for subsequent experiments. The results are shown in Table 1.

[0051] Table 1 Effects of granules on normal cells ( n=6)

[0052]

[0053]

[0054] 3) Aβ 1-42 Construction of SH-SY5Y cell model for induced injury: After SH-SY5Y cells were grown to cover 80-90% of the bottom of the bottle, they were digested and inoculated into 96-well plates. After complete attachment overnight, the supernatant was aspirated, washed with PBS three times, and Aβ was added 1-42 The damage was carried out and a control group was set up to investigate the degree of cell damage and construct a damage model. Different concentrations of Aβ were used 1-42 When SH-SY5Y cells were damaged, it was found that at a concentration of 25 μmol / mL, the cell damage was moderate and the survival rate was about 50%. Therefore, this concentration was selected as the modeling concentration for subsequent experiments. The results are shown in Table 2.

[0055] Table 2 Different concentrations of Aβ 1-42 Damage to cells ( n=8)

[0056]

[0057] 4) Aβ 1-42 Effect of induced damage on SH-SY5Y cell viability: After SH-SY5Y cells grew to 80-90% of the bottom of the bottle, they were digested and inoculated into 96-well plates. After complete attachment overnight, the supernatant was aspirated and washed with PBS three times. Except for the control group, Aβ was added to 1-42The mice in the drug administration group were treated with different concentrations of the granules of Example 3 and placed in a 37°C, 5% CO2 incubator for incubation. After 24 hours, the CCK-8 method was used to detect the effect of the granules of Example 3 on Aβ. 1-42 The effects of different concentrations of the granules (12.5 mg / mL, 6.25 mg / mL, 3.12 mg / mL) on Aβ 1-42 The protective effect of the granules in Example 3 on the damaged cells was induced, and the concentration was dose-dependent. The results are shown in Table 3. Compared with the control group, ##P<0.01; compared with the model group, **P<0.01;

[0058] Table 3 Granules against Aβ 1-42 Effect of induced damage on SH-SY5Y cell viability ( n=6)

[0059]

[0060] 5) The cells were seeded into 24-well plates, with 1×10 5 Cells were treated according to the method in 4). After the experiment, the supernatant was taken and the expression of NGF in the supernatant was determined using a nerve growth factor (NGF) detection kit. The results are shown in Table 4 and Figure 1 As shown, compared with the control group, ##P<0.01; compared with the model group, **P<0.01, *P<0.05; From the results, it can be seen that the granules of Example 3 at concentrations of 12.5 mg / mL, 6.25 mg / mL and 3.12 mg / mL can significantly increase Aβ 1-42 Expression of NGF in cells after injury.

[0061] Table 4 Aβ 1-42 Effect of inducing injury on NGF expression in SH-SY5Y cells n=6)

[0062]

[0063] Example 5 (Parkinson's disease)

[0064] The granules of Example 3 have the following effects on improving the memory of Parkinson's mice:

[0065] 1) Experimental grouping and drug administration: 72 male SPF C57BL mice weighing 18-22 g were randomly divided into 6 groups, with 12 mice in each group. The blank group was given normal saline, the model group was given MPTP modeling, the positive drug was given Madopar, and the high, medium and low doses of the granules of Example 3 were given 800 mg / kg, 400 mg / kg and 200 mg / kg of the granules of Example 3, respectively, for continuous gavage for 14 days, and pole climbing, tail suspension and tension measurement experiments were performed;

[0066] 2) Climbing pole experiment: prepare a small stick with a length of 35 cm and a diameter of 1 cm as the experimental climbing pole. Fix a small ball with a diameter of 2 cm on the top of the climbing pole. To prevent the mouse from slipping during the crawling process, wrap the small stick with about 3 to 4 layers of gauze in advance. During the test, place each mouse on the top of the small ball and let it climb down freely. The mouse’s climbing length is considered complete when both forelimbs touch the platform at the bottom of the pole. Record the time required for the mouse to climb the complete length. Each mouse repeats the climbing pole 3 times, and the scoring is as follows: 3 points within 3 seconds, 2 points within 6 seconds, and 1 point for more than 6 seconds. The experimental results are shown in Tables 5 and Figure 2 , compared with the blank group, ##P<0.01; compared with the model group, **P<0.01, *P<0.05. It can be seen that high, medium and low doses of granules can significantly improve the scores of the pole climbing test of mice in the model group (P<0.01), indicating that granules can improve the pole climbing ability of Parkinson's mice.

[0067] Table 5 Effects on climbing poles in Parkinson's mice ( n=12)

[0068] Group dose Pole climbing (points) Blank control 2.8±0.6 Model Group 1.1±0.3## Positive Drug 500mg / kg 2.4±0.5** Granules High Dose 800mg / kg 1.9±0.7** Medium dose of granules 400mg / kg 1.8±0.8** Granules low dose 200mg / kg 1.8±0.6**

[0069] 3) Tail suspension test: The front paws of the test mice were made to grasp a metal wire with a diameter of about 1mm and about 25cm above the ground for 10s. The scoring criteria were as follows: the test time was 10s, and if the mouse grasped with both paws within the test time, 3 points were given; if the mouse grasped with one paw, 2 points were given; if the mouse could not grasp with both paws, 1 point was given; and if the mouse fell, 0 points were given.

[0070] The results are shown in Table 6. Compared with the blank group, ##P<0.01; compared with the model group, **P<0.01, *P<0.05. It can be seen that the high and medium doses of granules can significantly improve the scores of the tail suspension test of mice in the model group (P<0.05). Although there is no statistical difference between the low dose group and the model group, it can improve the score of the tail suspension test, indicating that the granules can improve the tail suspension test score of Parkinson's mice and improve the grasping ability of the forelimbs of Parkinson's mice.

[0071] Table 6 Effects of tail suspension on Parkinson's mice ( n=12)

[0072] Group dose Tail suspension (points) Blank control 2.7±0.5 Model Group 1.0±1.0## Positive Drug 500mg / kg 1.8±0.6* Granules High Dose 800mg / kg 1.9±0.9* Medium dose of granules 400mg / kg 1.8±0.9* Granules low dose 200mg / kg 1.4±1.1

[0073] 4) Tensile force measurement experiment: Grasp the test mouse and place it on the gripping board, push the gripping board forward, slide the hand holding the mouse backward to the tail, gently release the gripping board, and let the gripping board slide backward with the gripping force of the mouse. After the mouse grabs the gripping board firmly, apply force and pull it backward in time to measure the maximum gripping force. Measure each mouse three times and record the data.

[0074] The results are shown in Table 7 and Figure 3 As shown, compared with the blank group, ##P<0.01; compared with the model group, **P<0.01, *P<0.05. It can be seen that high, medium and low doses of granules can significantly increase the pulling force of mice in the model group (P<0.01 or P<0.05), indicating that granules can improve the strength of the hanging forelimb grasping force of Parkinson's mice.

[0075] Table 7 Effects of pulling force on Parkinson's mice ( n=12)

[0076] Group dose Tension(g) Blank control 227.5±16.9 Model Group 147.0±9.8## Positive Drug 500mg / kg 173.3±10.3** Granules High Dose 800mg / kg 170.5±10.1** Medium dose of granules 400mg / kg 162.1±8.4** Granules low dose 200mg / kg 156.8±10.2*

[0077] Example 6 (Memory)

[0078] The granules prepared in Example 3 have the following effects on improving the memory of experimental mice:

[0079] 1) Experimental grouping and administration: 80 male SPF KM mice weighing 18-22 g were randomly divided into 2 groups, 40 mice in each group; the first group was subjected to a mouse platform jumping behavior experiment; the second group was subjected to a mouse dark avoidance behavior experiment; each group of animals was randomly divided into 5 groups, a blank control group, a model group, and high-, medium-, and low-dose groups of granules, with 8 mice in each group. The blank control group and the model group were given normal saline, and the high-, medium-, and low-dose granules of Example 3 were given 800 mg / kg, 400 mg / kg, and 200 mg / kg of the granules of Example 3, respectively, for continuous gavage for 30 days. Except for the blank control group, scopolamine 5 mg / kg was intraperitoneally injected for modeling, and platform jumping experiment and dark avoidance experiment were performed 4 weeks after administration;

[0080] 2) Platform jumping test: Place the mice in the reaction box to adapt to the environment for 3 minutes, then place them on the copper grid in the reaction box and immediately apply 36V AC. Train them for 5 minutes. After 24 hours, the test phase begins. The time when the mice first jump off the high platform is the platform jumping latency time, and the number of times they are shocked within 3 minutes is the number of errors.

[0081] The results are shown in Table 8 and Figure 4As shown, compared with the blank group, ##P<0.01; compared with the model group, **P<0.01, *P<0.05. It can be seen that compared with the model group, the latency and number of errors of mice in the high and medium dose groups were significantly reduced.

[0082] Table 8 Effects on latency and number of errors in the mouse jumping test ( n=8)

[0083] Group dose Incubation period(s) Number of errors (times) Blank control 75.1±8.2 5.1±1.6 Model Group 36.5±9.4## 8.0±1.8## Granules High Dose 800mg / kg 67.4±14.1** 5.3±2.0* Medium dose of granules 400mg / kg 59.8±11.3** 5.9±1.6* Granules low dose 200mg / kg 53.6±9.3** 7.3±1.4

[0084] 3) Dark avoidance experiment: First, each group of mice was placed in the light room of a dark avoidance box (a black rectangular dark avoidance box with two rooms, light and dark, and an electric current at the bottom of the dark room), and allowed to move freely for 3 minutes without electricity; then the mice were driven to the dark room with electricity, and each mouse was trained for 5 minutes. After an interval of 24 hours, the mice were placed in the light room with their faces facing away from the hole, and the partition was opened, and the timer was started at the same time. The time when the mouse first reached the dark room was the latent period; the number of times it entered the dark room and received electric shock was the number of errors. The latent period of each mouse and the number of errors of the mouse entering the dark room within 5 minutes were recorded.

[0085] The results are shown in Table 9 and Figure 5 As shown, compared with the blank group, ##P<0.01; compared with the model group, **P<0.01, *P<0.05. It can be seen that the particles can reduce the latency time of the dark avoidance test of mice and reduce the number of errors.

[0086] Table 9 Effects on the latency and number of errors in the dark avoidance test in mice ( n=8)

[0087]

[0088] In summary, the pharmaceutical composition of the present invention has an effect on Aβ 1-42 Induced damage to SH-SY5Y cells has a protective effect, can promote the synthesis of brain nerve growth factor (Nerve growth factor, NGF), can prevent and improve cognitive ability.

[0089] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention, not all of the embodiments. People can also obtain other embodiments based on this embodiment without creativity, and these embodiments all fall within the protection scope of the present invention.

Claims

1. A Chinese medicine prescription for treating neurodegenerative diseases, characterized in that: Includes the following Chinese medicinal ingredients: Hericium erinaceus, turmeric and purslane.

2. The Chinese medicine prescription according to claim 1, characterized in that: The invention comprises the following Chinese medicinal raw materials in parts by weight: 100-600 parts by weight of Hericium erinaceus, 30-100 parts by weight of turmeric and 90-150 parts by weight of purslane.

3. A Chinese medicine composition having a therapeutic effect on neurodegenerative diseases, characterized in that: Includes the following ingredients: Hericium erinaceus extract, turmeric extract and purslane extract.

4. The Chinese medicine composition according to claim 3, characterized in that: The invention comprises the following components in parts by weight: 10 to 120 parts by weight of Hericium erinaceus extract, 1 to 20 parts by weight of Curcuma longa extract and 15 to 40 parts by weight of Portulaca oleracea extract.

5. The Chinese medicine composition according to claim 3 or 4, characterized in that: The extraction solvents of the Hericium erinaceus extract, the turmeric extract and the purslane extract are all polar solvents.

6. The Chinese medicine composition according to claim 5, characterized in that: The polar solvent includes water and / or ethanol.

7. Use of the Chinese medicine formula according to claim 1 or 2 or the Chinese medicine composition according to any one of claims 3 to 6 in the preparation of drugs for treating neurodegenerative diseases.

8. A drug for treating neurodegenerative diseases, characterized in that: It comprises the Chinese medicine prescription according to claim 1 or 2 or the Chinese medicine composition according to any one of claims 3 to 6, and also comprises pharmaceutically acceptable excipients.

9. The drug according to claim 8, characterized in that: Active ingredients also include chemical drugs that are clinically used to treat neurodegenerative diseases.

10. The drug according to claim 8 or 9, characterized in that: The types of medicines include oral medicines.

Images